Blessing Ja
Impact in
- Obstetrics and Gynecology top 2%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
Papers in
-
- Ovarian cancer diagnosis and treatment 12
-
- Endometrial and Cervical Cancer Treatments 5
- Uterine Myomas and Treatments 4
- Co-authors
- Charles E. Mangan (1 shared paper)Buchsbaum Hj (1 shared paper)DiSaia Pj (3 shared papers)Creasman Wt (4 shared papers)Tate Thigpen (1 shared paper)B. Bundy (1 shared paper)Cynthia Angel (1 shared paper)Wallace Hj (1 shared paper)
- Journals
- Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) (2 papers)PubMed (15 papers)
- Partner nations
- United States
In The Last Decade
Blessing Ja
17 papers receiving 387 citations
Peers
Comparison fields: 5 of 37
- Obstetrics and Gynecology 298
- Reproductive Medicine 221
- Oncology 91
- Pulmonary and Respiratory Medicine 105
- Surgery 118
Countries citing papers authored by Blessing Ja
This map shows the geographic impact of Blessing Ja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Blessing Ja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Blessing Ja more than expected).
Fields of papers citing papers by Blessing Ja
This network shows the impact of papers produced by Blessing Ja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Blessing Ja. The network helps show where Blessing Ja may publish in the future.
Co-authors
The 16 scholars most cited alongside Blessing Ja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. | 1979 | 115 |
| 2 | Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. | 1986 | 60 |
| 3 | Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. | 1978 | 39 |
| 4 | Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. | 1980 | 39 |
| 5 | Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. | 1987 | 27 |
| 6 | Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. | 1984 | 26 |
| 7 | Current therapy of ovarian carcinoma: an overview. | 1985 | 23 |
| 8 | Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. | 1987 | 21 |
| 9 | Chemotherapy of gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina, and vulva. | 1978 | 18 |
| 10 | Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. | 1982 | 16 |
| 11 | Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. | 1984 | 12 |
| 12 | Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study. | 1979 | 10 |
| 13 | Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study. | 1987 | 4 |
| 14 | Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. | 1983 | 4 |
| 15 | Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study. | 1986 | 3 |
| 16 | Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study. | 1984 | 2 |
| 17 | Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. | 1983 | 2 |
About Blessing Ja
Blessing Ja is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Epidemiology and Genetics, having authored 17 papers that have together received 421 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (5 papers), Uterine Myomas and Treatments (4 papers), Lung Cancer Research Studies (3 papers), Cervical Cancer and HPV Research (2 papers), Estrogen and related hormone effects (2 papers), Cancer Research and Treatments (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Obstetrics and Gynecology (298 citations), Reproductive Medicine (221 citations), Oncology (91 citations), Pulmonary and Respiratory Medicine (105 citations) and Surgery (118 citations). Blessing Ja has collaborated with scholars based in United States. Frequent co-authors include Charles E. Mangan, Buchsbaum Hj, DiSaia Pj, Creasman Wt, Tate Thigpen, B. Bundy, Cynthia Angel, Wallace Hj, M. Berman and M Slavík. Their work appears in journals such as Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.